Promis Neurosciences (NASDAQ:PMN) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Posted by Brenda Bartman on Oct 28th, 2026

Shares of Promis Neurosciences (NASDAQ:PMN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $34.00.

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. Cantor Fitzgerald initiated coverage on shares of Promis Neurosciences in a research report on Tuesday, June 30th. They set an “overweight” rating on the stock. Roth Capital set a $29.00 target price on shares of Promis Neurosciences in a research note on Friday, August 21st. HC Wainwright reissued a “buy” rating on shares of Promis Neurosciences in a research note on Monday, October 12th. Finally, Guggenheim reissued a “buy” rating and issued a $69.00 price target (up from $35.00) on shares of Promis Neurosciences in a research report on Tuesday, July 28th.

Get Our Latest Research Report on Promis Neurosciences

Promis Neurosciences Stock Performance

PMN opened at $9.68 on Wednesday. The stock’s 50 day simple moving average is $11.63 and its 200-day simple moving average is $12.86. Promis Neurosciences has a 1 year low of $6.27 and a 1 year high of $27.40.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.10. As a group, equities analysts expect that Promis Neurosciences will post -5.07 earnings per share for the current year.

Hedge Funds Weigh In On Promis Neurosciences

A number of hedge funds have recently modified their holdings of PMN. Seven Fleet Capital Management LP acquired a new stake in Promis Neurosciences in the 1st quarter valued at $135,000. Janus Henderson Group PLC acquired a new position in Promis Neurosciences during the first quarter worth $16,418,000. Ally Bridge Group NY LLC lifted its holdings in shares of Promis Neurosciences by 66.1% during the first quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after acquiring an additional 164,880 shares during the period. Yu Fan bought a new position in shares of Promis Neurosciences during the first quarter valued at $4,188,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Promis Neurosciences during the first quarter valued at $1,211,000. 50.13% of the stock is owned by institutional investors and hedge funds.

About Promis Neurosciences

(Get Free Report)

ProMIS Neurosciences Inc (NASDAQ: PMN) is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases. The company’s research focuses on misfolded proteins, which can form toxic structures associated with conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and other neurological disorders.

ProMIS uses its proprietary target-discovery platform to identify disease-specific toxic protein conformations and develop antibodies intended to selectively bind and neutralize them while avoiding healthy forms of the same proteins.